During the last session, ImmunityBio Inc (NASDAQ:IBRX)’s traded shares were 2.7 million, with the beta value of the company hitting 0.71. At the end of the trading day, the stock’s price was $3.32, reflecting an intraday gain of 2.47% or $0.08. The 52-week high for the IBRX share is $10.53, that puts it down -217.17 from that peak though still a striking 31.33% gain since the share price plummeted to a 52-week low of $2.28. The company’s market capitalization is $2.42B, and the average trade volume was 5.76 million shares over the past three months.
ImmunityBio Inc (IBRX) received a consensus recommendation of Sell from analysts. That translates to a mean rating of 1.50. IBRX has a Sell rating from 1 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.13.
ImmunityBio Inc (NASDAQ:IBRX) trade information
ImmunityBio Inc (IBRX) registered a 2.47% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.47% in intraday trading to $3.32, hitting a weekly high. The stock’s 5-day price performance is 0.30%, and it has moved by 43.10% in 30 days. Based on these gigs, the overall price performance for the year is -29.96%.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 44.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, IBRX is trading at a discount of -80.72% off the target high and -80.72% off the low.
ImmunityBio Inc (IBRX) estimates and forecasts
In the rating firms’ projections, revenue will increase 3,312.86% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 9.51M as predicted by 4 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 23.09M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 139k and 40k respectively. In this case, analysts expect current quarter sales to grow by 6,738.31% and then jump by 57,618.75% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 1.17%. While earnings are projected to return 30.43% in 2025, the next five years will return 32.58% per annum.
IBRX Dividends
ImmunityBio Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 11.42 million shares, is of BLACKROCK INC.’s that is approximately 1.6978% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $72.19 million.
